Compare Abeona Therapeutics Inc (ABEO) vs 8x8 Inc (EGHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs 8x8 Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while 8x8 Inc trades at $1.96 (market cap $279.31M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | EGHT | |
|---|---|---|
Market Cap | $373.32M | $279.31M |
Sector | Health | Technology |
52-Week High | $7.23 | $2.76 |
52-Week Low | $4.17 | $1.59 |
Enterprise Value | $228.22M | $556.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EGHT (8x8, Inc.) trades at $1.94, up 6.01% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 EPS versus $0.07 expected. Recent news highlights AI product launches and industry recognition, including being named a 2026 MetriStar Top Provider for CPaaS. However, the company reported a net loss of $27.21 million for 2025, though projections show potential profitability improvement in 2026.
The outlook remains cautiously optimistic with analyst consensus showing 39% buy ratings but mixed technical indicators. Key opportunities include continued AI product adoption and revenue growth momentum, while risks center on profitability challenges, high debt levels, and competitive pressures in the communications platform market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
